AVTX- Avalo Therapeutics, Inc.

Name: Avalo Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 19 buys and 0 sells. AVTX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
Other	Boyd Taylor	275.0K	$4.04M	-
Other	Doyle Mittie	47.8K	$702.7K	-679
CFO	Sullivan Christopher Ryan	19.1K	$281.0K	-
Other	Varki Paul	3.6K	$53.4K	-
Dir	Chan Mitchell	3.2K	$46.5K	-

Activity

Buys and sells only

Transactions

10 filings · page 4

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 14, 2022	Armistice Capital, LLC56	Director, 10% Owner	Buy	455,000	$1.00	$452,767.93	+0.3%	-40.1%	-59.5%
Jan 11, 2022	Armistice Capital, LLC56	Director, 10% Owner	Buy	645,000	$1.00	$642,931.32	+0.5%	-33.5%	-56.4%
Dec 10, 2021	Wilkins H Jeffrey	Chief Medical Officer	Buy	6,371	$1.57	$10,002.47	+23.6%	-61.9%	-76.6%
Dec 10, 2021	Sullivan Christopher Ryan	Chief Accounting Officer	Buy	955	$1.57	$1,499.35	+11.9%	-61.9%	-76.6%
Dec 10, 2021	Harrell James Archie Jr	Chief Commercial Officer	Buy	1,093	$1.57	$1,716.01	+3.1%	-61.9%	-76.6%
Dec 10, 2021	Neil Garry Arthur	Chief Scientific Officer	Buy	4,267	$1.57	$6,699.19	+5.2%	-61.9%	-76.6%
Dec 10, 2021	Greenway Schond L.	CFO	Buy	2,231	$1.57	$3,502.67	+135.0%	-61.9%	-76.6%
Sep 17, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	5,700,000	$2.20	$12,557,901.85	+4.8%	-29.9%	-86.5%
Aug 18, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$2.76	$138,188.00	-	-19.8%	-85.3%
Aug 6, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	150,000	$2.72	$408,515.00	+0.1%	-16.0%	-88.3%

← PrevPage 4Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC